Please assess the completion status of the following clinical trial:

Trial Title: A Single Rising Dose Study of MK-8150 (MK-8150-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 50 years of age for Panels A, B and D, or between 18 and 60 years of age (inclusive) for Panel C.~* Systolic blood pressure (SBP) \> 110 and ≤ 140 mmHg for Panels A, B, and D or SBP values of 140-175 mmHg and diastolic blood pressure (DBP) of 90-105 mmHg on at least three different occasions at the prestudy (screening) visit for Panel C. Participants being treated with medication for their hypertension may be included as long as they are titrated off of their medication~* Body Mass Index (BMI) ≥ 18 kg/m\^2 and ≤ 32 kg/m\^2~* Healthy (with the exception of hypertensive subjects in Panel C)~* No clinically significant abnormality on electrocardiogram (ECG)~* No history of clinically significant cardiac disease~* No history of heart failure~* Nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6 months~Exclusion Criteria:~* Mentally or legally incapacitated~* History of stroke, chronic seizures, or major neurological disorder~* History of clinically significant endocrine, gastrointestinal, cardiovascular (except mild to moderate hypertension), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases~* Functional disability that can interfere with rising from a sitting position to the standing position~* History of neoplastic disease (cancer)~* Unable to refrain from or anticipates the use of any medication during the study~* Anticipates using medication for erectile dysfunction during the study~* Uses or anticipates using organic nitrates during the study (e.g. nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, pentaerythritol)~* Anticipates using cytochrome P450 inhibitors (e.g. ketoconazole) or inducers (e.g. rifampin) during the study~* Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages per day~* Consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, or other caffeinated beverages per day~* Has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 4 weeks~* History of significant multiple and/or severe allergies (including latex allergy)~* Regular user (including recreational user) of illicit drugs or has a history of drug (including alcohol) abuse within approximately 1 year

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Panel A-Healthy (Type: EXPERIMENTAL): Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel A will be 2.0 mg to 90 mg.
- Panel B-Healthy (Type: EXPERIMENTAL): Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel B will be 5.0 mg to 160 mg.
- Panel C-Mild/Moderate Hypertension (Type: EXPERIMENTAL): Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel C will be 160 mg to 1200 mg.
- Panel D-Healthy (Type: EXPERIMENTAL): Within each panel, 8 subjects will be randomly assigned to MK-8150 and 2 subjects will be randomly assigned to placebo throughout the 5 periods according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel D will be 50 mg to 500 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete